Doctor-Patient: The Niacin Discussion
(MedPage Today) -- Many physicians are finding themselves fielding a barrage of patient questions about heart disease this week due to headlines coming out of the American College of Cardiology's annual meeting in San Francisco. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 15, 2013 Category: Cardiology Source Type: news
Niacin And Laropiprant Combo Shows No Benefits, Has Some Harmful Effects In Patients With Vascular Disease
A highly anticipated study evaluating a combination of the vitamin niacin with the anti-flushing agent laropiprant finds the therapy provides no benefit to and may even be harmful for patients with vascular disease, according to research presented at the American College of Cardiology's 62nd Annual Scientific Session. Detailed trial data is presented here for the first time... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 12, 2013 Category: Consumer Health News Tags: Vascular Source Type: news
Conference report: Niacin/laropripant combination (Tredaptive) associated with increased risk of bleeding and infections
Source: Reuters Health News
Area: News
Reuters Health News has reported that according to data presented at the annual American College of Cardiology scientific meeting, niacin in combination with laropripant (Tredaptive) was associated with statistically significantly higher rates of bleeding (2.5% vs 1.9%), and infections (8.0% vs 6.6%) compared to patients taking simvastatin or simvastatin/ezetimibe. They called the differences unexpected.
Additionally, patients taking Tredaptive also experienced higher rates of serious health problems that researchers said are known side effects of niacin, which included ne...
Source: NeLM - Cardiovascular Medicine - March 12, 2013 Category: Cardiology Source Type: news
Niacin Won't Help, May Harm Heart Patients: Study
Taking the B vitamin offered no benefit in lowering cardiac deaths or heart attacks, researchers say
Source: HealthDay
Related MedlinePlus Pages: B Vitamins, Cholesterol, Statins (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - March 11, 2013 Category: Consumer Health News Source Type: news
Niacin Won't Help, May Harm Heart Patients: Study
Title: Niacin Won't Help, May Harm Heart Patients: StudyCategory: Health NewsCreated: 3/9/2013 2:35:00 PMLast Editorial Review: 3/11/2013 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - March 11, 2013 Category: Cardiology Source Type: news
Merck's Long-Acting Niacin Drug Has Serious Side Effects
Tredaptive, Merck & Co's long-acting niacin medication aimed at elevating HDL cholesterol (good cholesterol) has unexpected serious side effects, researchers announced on Saturday. This is more evidence against using niacin therapy for heart patients. A major study (HPS2-THRIVE) found that Tredaptive, which consist of the vitamin niacin combined with anti-flushing agent laropiprant, provides no benefit and may even be hazardous for patients with vascular disease... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 11, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news
Big Bucks, No Benefits with Many Drugs
(MedPage Today) -- Cardiologists meeting in San Francisco were told that extended-release niacin has no measurable benefits in heart disease and many risks. But niacin is not the only popular treatment that piles up profits without proof. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 10, 2013 Category: Cardiology Source Type: news
Niacin Full Results in HPS2-THRIVE Aired at ACCNiacin Full Results in HPS2-THRIVE Aired at ACC
Regarding the primary end point, the combination of coronary death, nonfatal MI, stroke, or coronary revascularization occurred in 15.0% of patients in the control arm and 14.5% of patients in the niacin/laropiprant arm, a difference that was not statistically significant. Equally important, the researchers also documented a significantly increased risk of adverse events with niacin/laropiprant, w Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 10, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news
ACC: HPS2-THRIVE May Signal the End for Niacin (CME/CE)
SAN FRANCISCO (MedPage Today) -- Results from a landmark study of specially formulated niacin in more than 25,000 high-risk patients appears to have extinguished any clinical role for niacin to reduce the risk of cardiovascular events in these patients, researchers said here. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 9, 2013 Category: Cardiology Source Type: news
Serious side effects seen with failed Merck niacin drug
SAN FRANCISCO (Reuters) - Unexpected serious side effects arose in a huge study of a Merck & Co long-acting niacin drug aimed at raising good HDL cholesterol, according to data released on Saturday, possibly adding another nail to the coffin of niacin therapy for heart patients. (Source: Reuters: Health)
Source: Reuters: Health - March 9, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Niacin Won't Help, May Harm Heart Patients
Taking the B vitamin offered no benefit in lowering cardiac deaths or heart attacks, researchers say
Source: HealthDay
Related MedlinePlus Pages: B Vitamins, Cholesterol, Statins (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - March 9, 2013 Category: Consumer Health News Source Type: news
Results from HPS2-THRIVE Study of TREDAPTIVE™ (extended-release niacin/laropiprant) Presented at American College of Cardiology Scientific Sessions
Dateline City:
SAN FRANCISCO
SAN FRANCISCO--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that researchers from the Clinical Trial Service Unit at
Oxford University presented results from the HPS2-THRIVE (Heart Protection
Study 2-Treatment of HDL to Reduce the Incidence
of Vascular Events) study of TREDAPTIVE™(extended-release
niacin/laropiprant) during a late-breaking clinical trials session at
the American College of Cardiology 62nd Annual Scientific
Ses...
Source: Merck.com - Research and Development News - March 9, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Latest News Source Type: news
Nicotinic Acid Under Review by EMA, Following HPS2-THRIVENicotinic Acid Under Review by EMA, Following HPS2-THRIVE
Agencies worldwide suspended the marketing of niacin/laropiprant products in January; the new announcement from the European regulator is extending the review to products containing only nicotinic acid (or related substances). Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 8, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news
EMA launches review of nicotinic acid on eve of HPS2-THRIVE late-breaker
Agencies worldwide suspended the marketing of niacin/laropiprant products in January; the new announcement from the European regulator is extending the review to products containing only nicotinic acid (or related substances). (Source: theHeart.org)
Source: theHeart.org - March 8, 2013 Category: Cardiology Source Type: news
ACC: Eyes Are on Watchman, Niacin
SAN FRANCISCO (MedPage Today) -- The Watchman left atrial appendage closure device and details from a failed niacin trial will be in the spotlight when the American College of Cardiology meeting kicks off Saturday. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 7, 2013 Category: Cardiology Source Type: news
